Alfametildopa - Used for: Treating high blood pressure. It may be used with other high blood pressure medicines. It may also be used for other conditions as determined by your doctor.
Alfametildopa is an alpha-2 receptor agonist. It reduces elevated blood pressure by relaxing and dilating (widening) blood vessels. Blood flows more freely and at a lower pressure through dilated blood vessels.
Alfametildopa lowers blood pressure by decreasing the levels of certain chemicals in your blood. This allows your blood vessels (veins and arteries) to relax (widen) and your heart to beat more slowly and easily.
Alfametildopa is used to treat hypertension (high blood pressure).
Alfametildopa may also be used for purposes not listed in this medication guide.
Alfametildopa is an aromatic-amino-acid decarboxylase inhibitor in animals and in man. Only methyldopa, the L-isomer of alpha-methyldopa, has the ability to inhibit dopa decarboxylase and to deplete animal tissues of norepinephrine. In man the antihypertensive activity appears to be due solely to the L-isomer. About twice the dose of the racemate (DL-alpha-methyldopa) is required for equal antihypertensive effect. Alfametildopa has no direct effect on cardiac function and usually does not reduce glomerular filtration rate, renal blood flow, or filtration fraction. Cardiac output usually is maintained without cardiac acceleration. In some patients the heart rate is slowed. Normal or elevated plasma renin activity may decrease in the course of Alfametildopa therapy. Alfametildopa reduces both supine and standing blood pressure. Alfametildopa usually produces highly effective lowering of the supine pressure with infrequent symptomatic postural hypotension. Exercise hypotension and diurnal blood pressure variations rarely occur.
Adult: Monotherapy: Initially, 250 mg bid-tid for 2 days; adjust according to response not more than every 2 days.
Maintenance: 0.5-2 g daily. Max: 3 g daily. Combination therapy: Initial dose should not exceed 500 mg daily in divided doses.
Child: Initially, 10 mg/kg or 300 mg/m 2 daily in 2-4 divided doses; increase as necessary. Max: 65 mg/kg, 2 g/m 2 or 3 g daily, whichever is least.
Elderly: Initially, 125 mg bid; gradually increase according to response. Max: 2 g daily. Renal impairment: May respond to smaller doses. Intravenous Hypertension
Adult: As methyldopate hydrochloride: 250-500 mg in 100 ml of 5% glucose injected over 30-60 min every 6 hr. Max: 1 g every 6 hr.
Child: As methyldopate hydrochloride: 20-40 mg/kg/24 hr or 0.6-1.2 g/m 2 /24 hr in equally divided doses every 6 hr. Max 65 mg/kg, 2 g/m 2 or 3 g daily, whichever is least. Renal impairment: May respond to smaller doses. Incompatibility: Incompatible with amphotericin B, methohexital.
Adult: PO HTN Monotherapy: Initial: 250 mg 2-3 times/day for 2 days; adjust accordingly not more than every 2 days.
Maintenance: 0.5-2 g/day. Max: 3 g/day. IV As methyldopate HCl: 250-500 mg 6 hrly. Max: 1 g 6 hrly.